利用数据集评估临床队列的外推性:以EQUAL研究为例
本研究利用THIN数据库评估EQUAL队列(>65岁CKD 4/5期)的外推性,比较EQUAL、初级保健队列(PCC)和二级保健队列(SCC)患者特征。EQUAL中男性比例更高,高龄和合并症与不参与相关;EQUAL患者1年RRT启动率高于SCC,而PCC和SCC的住院和死亡风险显著高于EQUAL。
要点
- EQUAL队列男性比例高于PCC和SCC。
- 年龄≥85岁和Charlson合并症指数≥4与不参与EQUAL相关。
- EQUAL的1年RRT启动率高于SCC,但PCC和SCC的住院和死亡风险更高。
核心结论
- 队列研究参与者与 broader 患者人群存在差异,评估外推性对本地实践应用至关重要。
研究设计与样本
- 利用THIN数据库识别符合EQUAL纳入标准的患者,分为EQUAL、PCC和SCC三组进行比较。
- EQUAL、PCC和SCC分别纳入250、633和2464例患者。
主要发现
- EQUAL男性比例60.0%,PCC为34.8%,SCC为51.4%。
- 年龄≥85岁(OR 0.25,95%CI 0.15-0.40)和Charlson合并症指数≥4(OR 0.69,95%CI 0.52-0.91)与不参与EQUAL相关。
- EQUAL 1年RRT启动率8.1%,SCC为2.1%(P<0.001)。
- PCC和SCC的住院风险分别为IRR 1.76(95%CI 1.27-2.47)和2.13(95%CI 1.59-2.86),1年死亡风险分别为HR 3.48(95%CI 2.1-5.7)和1.7(95%CI 1.1-2.7),均高于EQUAL。
临床怎么用
- 解读队列研究结果时需考虑参与者与目标人群的差异,谨慎外推至本地实践。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cohort studies are among the most robust of observational studies but have issues with external validity. This study assesses threats to external validity (generalizability) in the European QUALity (EQUAL) study, a cohort study of people >65 years of age with Stage 4/5 chronic kidney disease. METHODS: Patients meeting the EQUAL inclusion criteria were identified in The Health Improvement Network database and stratified into those attending renal units, a secondary care cohort (SCC) and a not primary care cohort (PCC). Survival, progression to renal replacement therapy (RRT) and hospitalization were compared. RESULTS: The analysis included 250, 633 and 2464 patients in EQUAL, PCC and SCC. EQUAL had a higher proportion of men compared with PCC and SCC (60.0% versus 34.8% versus 51.4%). Increasing age ≥85 years {odds ratio [OR] 0.25 [95% confidence interval (CI) 0.15-0.40]} and comorbidity [Charlson Comorbidity Index ≥4, OR 0.69 (95% CI 0.52-0.91)] were associated with non-participation in EQUAL. EQUAL had a higher proportion of patients starting RRT at 1 year compared with SCC (8.1% versus 2.1%; P < 0.001). Patients in the PCC and SCC had increased risk of hospitalization [incidence rate ratio 1.76 (95% CI 1.27-2.47) and 2.13 (95% CI 1.59-2.86)] and mortality at 1 year [hazard ratio 3.48 (95% CI 2.1-5.7) and 1.7 (95% CI 1.1-2.7)] compared with EQUAL. CONCLUSIONS: This study provides evidence of how participants in a cohort study can differ from the broader population of patients, which is essential when considering external validity and application to local practice.
引用
- Rao A, MacNeill SJ, van de Luijtgaarden MWM, et al. Using datasets to ascertain the generalizability of clinical cohorts: the example of the European QUALity study on the treatment of advanced chronic kidney disease. Nephrol Dial Transplant. 2022. PMID: 33426560. doi:10.1093/ndt/gfab002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。